Desmopressin

Summary

Desmopressin (CHEMBL1429) is an approved protein vasopressin receptor agonist (ATC H01BA02) targeting AVPR1A, AVPR1B, and AVPR2; indicated across 10 conditions including diabetes insipidus and enuresis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: H01BA02
• Targets: 4 (AVPR1A, AVPR1B, AVPR2…)
• Indications: 10 conditions
• Clinical trials: 75
• Chemistry: 1069.2 Da · C46H64N14O12S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1429
Name	Desmopressin
Type	Protein
Max phase	4
FDA approved	yes
PubChem CID	5311065
ChEBI	CHEBI:4450
ATC	H01BA02
Molecular formula	C46H64N14O12S2
Molecular weight	1069.2
InChIKey	NFLWUMRGJYTJIN-PNIOQBSNSA-N

SMILES: C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N

IUPAC name: (2S)-N-[(2R)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide

ChEBI definition: A synthetic analogue of vasopressin in which 3-mercaptopropionic acid replaces the cysteine residue at position 1 and D-arginine replaces the residue at position 8. An antidiuretic, it increases urine concentration and decreases urine production, and is used (usually as the trihydrate of the acetic acid salt) to prevent and control excessive thirst, urination, and dehydration caused by injury, surgery, and certain medical conditions. It is also used in the diagnosis and treatment of cranial diabetes insipidus and in tests of renal function.

Pharmacological roles (ChEBI): vasopressin receptor agonist, renal agent, diagnostic agent.

Also known as: Desmopresina, Desmopressin, Desmopressine, H01BA02, Ser-120, Ser120, deamino-AVP, deamino-[Cys1]arginine vasopressin, dDAVP, ddavp, DESMOPRESSINE, SID144206930

Parent form; salt/anhydrous children: CHEMBL1200556

Patent coverage: 60 distinct patent families (122 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 92 (75%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
AVPR1A	V1A receptor	Full agonist	7.7	4.6%	P37288
AVPR1B	V1B receptor	Full agonist	8.2	0.4%	P47901
AVPR2	V2 receptor	Full agonist	8.6	0%	P30518
OXTR	OT receptor	Full agonist	7.6	0.1%	P30559

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Vasopressin V2 receptor, Vasopressin V1a receptor, Vasopressin V1b receptor, Oxytocin receptor, Prostaglandin G/H synthase 1, Vasopressin V1b receptor, Vasopressin V1a receptor, Vasopressin V2 receptor, Oxytocin receptor.

Bioactivity

ChEMBL activities: 24 potent at pChembl ≥ 5 of 24 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q00788	10.52	EC50	0.03	nM	CHEMBL_ACT_19232160
AVPR2	9.7	EC50	0.2	nM	CHEMBL_ACT_15001077
P48974	9.7	Ki	0.2	nM	CHEMBL_ACT_1818260
AVPR2	9.7	EC50	0.2	nM	CHEMBL_ACT_19231809
AVPR2	9.7	EC50	0.2	nM	CHEMBL_ACT_29077837
Q00788	9.52	Ki	0.3	nM	CHEMBL_ACT_1818264
AVPR1B	9.43	Ki	0.37	nM	CHEMBL_ACT_769372
Q00788	9.1	Ki	0.8	nM	CHEMBL_ACT_1818265
P70536	9.01	Ki	0.97	nM	CHEMBL_ACT_1818272
AVPR1A	8.42	Ki	3.8	nM	CHEMBL_ACT_769373
AVPR2	8.3	Ki	5	nM	CHEMBL_ACT_769374
OXTR	8.3	Ki	5	nM	CHEMBL_ACT_769375
AVPR1B	8.24	Ki	5.8	nM	CHEMBL_ACT_786413
P30560	7.97	Ki	10.8	nM	CHEMBL_ACT_1818270
AVPR1B	7.96	EC50	11	nM	CHEMBL_ACT_15001212
AVPR1B	7.96	EC50	11	nM	CHEMBL_ACT_19231866
AVPR2	7.63	Ki	23.3	nM	CHEMBL_ACT_786415
AVPR1A	7.21	Ki	62.4	nM	CHEMBL_ACT_786414
OXTR	7.14	EC50	72	nM	CHEMBL_ACT_15001065
P30560	7	Ki	100	nM	CHEMBL_ACT_1818269
OXTR	6.96	EC50	110	nM	CHEMBL_ACT_19231852
AVPR2	6.66	EC50	220	nM	CHEMBL_ACT_27021584
PTGS1	5.44	AC50	3621	nM	CHEMBL_ACT_25205754
AVPR1B	5.18	EC50	6590	nM	CHEMBL_ACT_27021587

Target pathways

Aggregated over 4 target gene(s): AVPR1A, AVPR1B, AVPR2, OXTR.

Top Reactome pathways

8 total, by targets touching each:

Pathway	Targets	Genes
Vasopressin-like receptors	4	AVPR1A, AVPR1B, AVPR2, OXTR
G alpha (q) signalling events	3	AVPR1A, AVPR1B, OXTR
Defective AVP does not bind AVPR1A,B and causes neurohypophyseal diabetes insipidus (NDI)	2	AVPR1A, AVPR1B
G alpha (s) signalling events	1	AVPR2
Vasopressin regulates renal water homeostasis via Aquaporins	1	AVPR2
Cargo recognition for clathrin-mediated endocytosis	1	AVPR2
Clathrin-mediated endocytosis	1	AVPR2
Defective AVP does not bind AVPR2 and causes neurohypophyseal diabetes insipidus (NDI)	1	AVPR2

Dominant GO biological processes

GO term	Targets
regulation of systemic arterial blood pressure by vasopressin	4
G protein-coupled receptor signaling pathway	4
cellular response to hormone stimulus	4
positive regulation of vasoconstriction	4
signal transduction	4
positive regulation of blood pressure	3
positive regulation of systemic arterial blood pressure	2
positive regulation of cytosolic calcium ion concentration	2
positive regulation of cell population proliferation	2
telencephalon development	2
transport across blood-brain barrier	2
regulation of blood pressure	2
maternal aggressive behavior	1
generation of precursor metabolites and energy	1
negative regulation of female receptivity	1

Indications & clinical

Indications

6 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
diabetes insipidus	3	MONDO:0004782	MONDO:0004782
enuresis	3	MONDO:0024290	MONDO:0024290
leptospirosis	2	MONDO:0005825	EFO:0007344
overactive bladder	2	MONDO:0006624	EFO:1000781
breast neoplasm	2	MONDO:0021100	MONDO:0007254
hypertensive disorder	1	MONDO:0005044	EFO:0000537

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 75.

Phase distribution

Phase	Trials
Not specified	22
PHASE4	19
PHASE3	17
PHASE2	9
PHASE1	4
PHASE2/PHASE3	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06622187	PHASE4	ENROLLING_BY_INVITATION	Bleeding Prevention With Desmopressin for Allograft Kidney Biopsies
NCT00337766	PHASE4	COMPLETED	Desmopressin in Cardiac Surgery
NCT00748072	PHASE4	COMPLETED	1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy
NCT00885924	PHASE4	TERMINATED	Desmopressin as Treatment for Postoperative Bleeding After Cardiac Surgery
NCT00902057	PHASE4	UNKNOWN	Desmopressin for Bleeding Related to Low Body Temperature
NCT00902655	PHASE4	COMPLETED	Desmopressin in the Treatment of Mixed Nocturia With Nocturnal Polyuria and Low Nocturnal Bladder Capacity
NCT01036841	PHASE4	COMPLETED	Influence of Food-intake on Desmopressin Oral Tablets and MELT-formulation
NCT01435083	PHASE4	COMPLETED	Desmopressin Melt Therapy in Patients With Nocturnal Polyuria: a Pharmacokinetic/Dynamic Study
NCT01439997	PHASE4	COMPLETED	Desmopressin Melt Therapy in Nocturnal Polyuria Patients: Pharmacodynamic Study
NCT01582542	PHASE4	UNKNOWN	Desmopressin for Improving Nocturnal Enuresis in Patients After Radical Cystectomy With Bladder Reconstruction
NCT01994330	PHASE4	COMPLETED	Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery
NCT02125188	PHASE4	COMPLETED	Effects of Desmopressin on Blood Loss and the Quality of the Surgical Field During Endoscopic Sinus Surgery
NCT02584231	PHASE4	COMPLETED	Pharmacokinetics and Pharmacodynamics of Desmopressin Oral Lyophilisate Formulation in the Paediatric Population
NCT03136003	PHASE4	UNKNOWN	DDAVP vs. Exercise in Patients With Mild Hemophilia A
NCT03343418	PHASE4	UNKNOWN	Effects of Prophylactic Desmopressin on Blood Coagulation Parameters in Heart Valve Surgery
NCT03389412	PHASE4	COMPLETED	The Effect of Selecting Treatment With Desmopressin or Alarm to Children With Enuresis Based on Home Recordings.
NCT03676361	PHASE4	WITHDRAWN	To Evaluate the Renal Tubular Function Pre and Post Nephrectomy in Living Donors
NCT04420585	PHASE4	TERMINATED	Desmopressin for Bedwetting in Children With SCD
NCT06255366	PHASE4	UNKNOWN	Analysis of the Clinical Efficacy of Intravenous Application of Hemostatic Drugs in Improving the Clarity of Vision Under Endoscope, Perioperative Bleeding Volume and Anti-inflammatory Effect of Spinal Endoscopic Lumbar Fusion
NCT05467033	PHASE3	RECRUITING	Safety Outcomes Post Kidney Biopsy - Randomized Clinical Evaluation of Efficacy of Desmopressin
NCT06020495	PHASE3	RECRUITING	Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia
NCT07199894	PHASE3	RECRUITING	Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE
NCT00230594	PHASE3	COMPLETED	Desmopressin Response in the Young
NCT00592566	PHASE2/PHASE3	TERMINATED	Desmopressin and Dexamethasone Adjunctive Treatment for Leptospirosis
NCT00615836	PHASE3	COMPLETED	An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving (Melt) Formulation of Desmopressin for the Treatment of Nocturia in Adults
NCT00937378	PHASE3	COMPLETED	Treatment of Patients With Nocturia (Non-PK Study)
NCT00937859	PHASE3	COMPLETED	Treatment of Patients With Nocturia
NCT00981682	PHASE3	COMPLETED	Long Term Safety Assessment of SER120 in Patients With Nocturia
NCT01078753	PHASE3	COMPLETED	Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis
NCT01223937	PHASE3	COMPLETED	Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients
NCT01262456	PHASE3	COMPLETED	Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients
NCT01280188	PHASE3	COMPLETED	A Study of Minirin Melt in Japanese Patients With Central Diabetes Insipidus (CDI).
NCT01357356	PHASE2/PHASE3	COMPLETED	Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia
NCT01530451	PHASE3	TERMINATED	Clinical Trial of Desmopressin on Nocturia in Obstructive Sleep Apnoea Patients
NCT01552343	PHASE3	COMPLETED	Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary
NCT01900704	PHASE3	COMPLETED	Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4
NCT02262936	PHASE2/PHASE3	TERMINATED	Comparison Between Desmopressin and Fesoterodine for Treatment of Night Time Voiding in Women Aged 65 and Older
NCT02904759	PHASE3	COMPLETED	Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects
NCT02905682	PHASE3	COMPLETED	Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects
NCT06635629	PHASE2	RECRUITING	Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome
NCT01184859	PHASE2	COMPLETED	Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo
NCT01606072	PHASE2	COMPLETED	Perioperative Use of Desmopressin (DDAVP) in Breast Cancer
NCT01623206	PHASE2	COMPLETED	Desmopressin (DDAVP) in Patients With Colorectal Cancer and Rectal Bleeding
NCT01779466	PHASE2	TERMINATED	Daytime Impact Sleep Study
NCT01982760	PHASE2	TERMINATED	DDAVP in the Reduction of Post-operative Ecchymosis in Rhinoplasty
NCT03201419	PHASE2	COMPLETED	A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults
NCT03696121	PHASE2	COMPLETED	Desmopressin for Reversal of Antiplatelet Drugs in Stroke Due to Haemorrhage
NCT05430048	PHASE2	COMPLETED	Nasal Desmopressin Versus Oral Bisoprolol for Controlling Bleeding During Endoscopic Sinus Surgery
NCT00223717	PHASE1	COMPLETED	Treatment of Supine Hypertension in Autonomic Failure
NCT01841515	PHASE1	COMPLETED	Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Drug
NCT02506023	PHASE1	COMPLETED	Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers
NCT04103034	PHASE1	COMPLETED	A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers
NCT04113005	EARLY_PHASE1	UNKNOWN	Safety and Tolerability Analysis of Combining Desmopressin With Docetaxel for the Treatment of Castration-Resistant Prostate Cancer
NCT00004363	Not specified	COMPLETED	Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus
NCT00004364	Not specified	UNKNOWN	Study of Novel Types of Familial Diabetes Insipidus
NCT00816127	Not specified	COMPLETED	Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction
NCT00902265	Not specified	COMPLETED	Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)
NCT01382134	Not specified	COMPLETED	Effect of Aspirin, Hemodilution and Desmopressin on Platelet Dysfunction
NCT01403740	Not specified	UNKNOWN	Turkish Acquired Haemophilia Registry
NCT01534117	Not specified	COMPLETED	Platelet Function Analysis in Head Trauma: ASA/Plavix
NCT02068560	Not specified	COMPLETED	The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion
NCT02084342	Not specified	UNKNOWN	Study of DDAVP Combined With TXA on the Blood Loss and Transfusion Need During and After Scoliosis Correction Surgery
NCT02368730	Not specified	COMPLETED	Documentation of the Efficacy of Desmopressin Within the Context of Surgical Procedures
NCT02636387	Not specified	TERMINATED	Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease
NCT02937896	Not specified	COMPLETED	Intranasal Desmopressin vs IV Ketorolac in Renal Colic Pain Control
NCT03089073	Not specified	TERMINATED	Study of Minirin Melt® in Adult Patients With Nocturia
NCT03733873	Not specified	COMPLETED	Study on Chinese and Western Medicine in MNE Children
NCT04329975	Not specified	COMPLETED	Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet (Nocturia)
NCT05507476	Not specified	COMPLETED	Nasal Desmopressin Versus Topical Epinephrine in Endonasal Dacryocystorhinostomy
NCT05617664	Not specified	UNKNOWN	Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis
NCT05628558	Not specified	UNKNOWN	Genetic Influence of Genetic Factors Influencing the Desmopressin’s Efficacy in Mild/Moderate Hemophilia A
NCT06020456	Not specified	COMPLETED	Genetic Factors of the Desmopressin Response in Carriers of Hemophilia A
NCT06185361	Not specified	UNKNOWN	Selective Serotonin Reuptake Inhibitors, Fluoxetine Versus the Standard Oral Desmopressin for Management of Mono-symptomatic Nocturnal Enuresis.
NCT06285006	Not specified	UNKNOWN	Desmopressin Monotherapy for Monosymptomatic Nocturnal Enuresis
NCT07292753	Not specified	COMPLETED	Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

143 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
OXYTOCIN	ChEMBL + PubChem	Phase 4 (approved)	AVPR1A, AVPR1B, AVPR2, OXTR
ATOSIBAN	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR1B, AVPR2, OXTR
CARBETOCIN	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR1B, AVPR2, OXTR
MOZAVAPTAN	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR1B, AVPR2, OXTR
VASOPRESSIN	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR1B, AVPR2, OXTR
NELIVAPTAN	ChEMBL	Phase 2	AVPR1A, AVPR1B, AVPR2, OXTR
ORNIPRESSIN	ChEMBL	Phase 2	AVPR1A, AVPR1B, AVPR2, OXTR
PECAVAPTAN	ChEMBL	Phase 2	AVPR1A, AVPR1B, AVPR2, OXTR
SELEPRESSIN	ChEMBL	Phase 2	AVPR1A, AVPR1B, AVPR2, OXTR
LIXIVAPTAN	ChEMBL	Phase 3	AVPR1A, AVPR2, OXTR
Belzutifan	PubChem	Approved	AVPR1A, AVPR2, OXTR
PIMOZIDE	ChEMBL + PubChem	Phase 4 (approved)	AVPR1A, AVPR2
RIFAMPIN	ChEMBL + PubChem	Phase 4 (approved)	AVPR1A, AVPR2
TEGASEROD	ChEMBL + PubChem	Phase 4 (approved)	AVPR1A, AVPR2
BALSALAZIDE	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR2
BOSUTINIB	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR2
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR2
CONIVAPTAN	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR2
FLUSPIRILENE	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR2
NITAZOXANIDE	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR2
PYRVINIUM	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR2
RIFAXIMIN	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR2
TOLVAPTAN	ChEMBL	Phase 4 (approved)	AVPR1A, AVPR2
BALOVAPTAN	ChEMBL	Phase 3	AVPR1A, AVPR2
NOLASIBAN	ChEMBL	Phase 3	AVPR1A, OXTR
OTILONIUM BROMIDE	ChEMBL	Phase 3	AVPR1A, AVPR2
RETOSIBAN	ChEMBL	Phase 3	AVPR2, OXTR
SEMAXANIB	ChEMBL	Phase 3	AVPR1A, OXTR
BENZETHONIUM	ChEMBL	Phase 2	AVPR1A, AVPR2
DOMIPHEN	ChEMBL	Phase 2	AVPR1A, AVPR2
EPELSIBAN	ChEMBL	Phase 2	AVPR2, OXTR
RELCOVAPTAN	ChEMBL	Phase 2	AVPR1A, AVPR2
Abiraterone	PubChem	Approved	AVPR1A, AVPR2
acetylcysteine	PubChem	Approved	AVPR1A, AVPR2
Aclidinium Bromide	PubChem	Approved	AVPR1A, AVPR2
Acyclovir	PubChem	Approved	AVPR1A, AVPR2
Afatinib	PubChem	Approved	AVPR1A, AVPR2
Allopurinol	PubChem	Approved	AVPR1A, AVPR2
Almotriptan	PubChem	Approved	AVPR1A, AVPR2
Alogliptin	PubChem	Approved	AVPR1A, AVPR2
aminolevulinic acid	PubChem	Approved	AVPR1A, AVPR2
Anagrelide	PubChem	Approved	AVPR1A, AVPR2
Apixaban	PubChem	Approved	AVPR1A, AVPR2
Aprepitant	PubChem	Approved	AVPR1A, AVPR2
Bosentan	PubChem	Approved	AVPR1A, AVPR2
Clofarabine	PubChem	Approved	AVPR1A, AVPR2
Clozapine	PubChem	Approved	AVPR1A, AVPR2
Crizotinib	PubChem	Approved	AVPR1A, AVPR2
Dacarbazine	PubChem	Approved	AVPR1A, AVPR2
Desloratadine	PubChem	Approved	AVPR1A, AVPR2
Desoxycorticosterone Pivalate	PubChem	Approved	AVPR1A, AVPR2
Didanosine	PubChem	Approved	AVPR1A, AVPR2
Dihydroergotamine	PubChem	Approved	AVPR1A, AVPR2
Erythromycin	PubChem	Approved	AVPR1A, AVPR2
Ethambutol	PubChem	Approved	AVPR1A, AVPR2
Fidaxomicin	PubChem	Approved	AVPR1A, AVPR2
Fulvestrant	PubChem	Approved	AVPR1A, AVPR2
Ganciclovir	PubChem	Approved	AVPR1A, AVPR2
Gefitinib	PubChem	Approved	AVPR1A, AVPR2
Glycopyrrolate	PubChem	Approved	AVPR1A, AVPR2
Leucovorin	PubChem	Approved	AVPR1A, AVPR2
Linagliptin	PubChem	Approved	AVPR1A, AVPR2
Methotrexate	PubChem	Approved	AVPR1A, AVPR2
Olanzapine	PubChem	Approved	AVPR1A, AVPR2
Olmesartan Medoxomil	PubChem	Approved	AVPR1A, AVPR2
Pramipexole	PubChem	Approved	AVPR1A, AVPR2
Propoxyphene	PubChem	Approved	AVPR1A, AVPR2
Pyrazinamide	PubChem	Approved	AVPR1A, AVPR2
Rufinamide	PubChem	Approved	AVPR1A, AVPR2
saxagliptin	PubChem	Approved	AVPR1A, AVPR2
Sildenafil	PubChem	Approved	AVPR1A, AVPR2
Tadalafil	PubChem	Approved	AVPR1A, AVPR2
Tafamidis	PubChem	Approved	AVPR1A, AVPR2
Tamsulosin	PubChem	Approved	AVPR1A, AVPR2
Tiotropium Bromide Monohydrate	PubChem	Approved	AVPR1A, AVPR2
Valacyclovir	PubChem	Approved	AVPR1A, AVPR2
Valganciclovir	PubChem	Approved	AVPR1A, AVPR2
CINACALCET	ChEMBL + PubChem	Phase 4 (approved)	AVPR2
AMIODARONE	ChEMBL	Phase 4 (approved)	AVPR2
AMOXAPINE	ChEMBL	Phase 4 (approved)	AVPR2
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	AVPR1A
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	AVPR2
DAUNORUBICIN	ChEMBL	Phase 4 (approved)	AVPR1A
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	AVPR1A
EPALRESTAT	ChEMBL	Phase 4 (approved)	AVPR1A
IDEBENONE	ChEMBL	Phase 4 (approved)	AVPR2
INDOCYANINE GREEN ACID FORM	ChEMBL	Phase 4 (approved)	AVPR1A
IPRINDOLE	ChEMBL	Phase 4 (approved)	AVPR2
ITRACONAZOLE	ChEMBL	Phase 4 (approved)	AVPR2
LASOFOXIFENE	ChEMBL	Phase 4 (approved)	AVPR2
MEFLOQUINE	ChEMBL	Phase 4 (approved)	AVPR2
NEBIVOLOL	ChEMBL	Phase 4 (approved)	AVPR2
NERATINIB	ChEMBL	Phase 4 (approved)	AVPR2
NIMESULIDE	ChEMBL	Phase 4 (approved)	AVPR2
PONATINIB	ChEMBL	Phase 4 (approved)	AVPR1A
RIMONABANT	ChEMBL	Phase 4 (approved)	AVPR1A
RITONAVIR	ChEMBL	Phase 4 (approved)	AVPR1A
SAQUINAVIR	ChEMBL	Phase 4 (approved)	AVPR1A
SERTINDOLE	ChEMBL	Phase 4 (approved)	AVPR2
SERTRALINE	ChEMBL	Phase 4 (approved)	AVPR2